Neutralizing VEGF Bioactivity with a Soluble Chimeric VEGF-Receptor Protein flt(I-3) IgG Inhibits Testosterone-Stimulated Prostate Growth in Castrated Mice

Prostate

Volumn 58, Issue 1, 2004, Pages 57-65

  Lissbrant, Ingela Franck ^a   Hammarsten, Peter ^a   Lissbrant, Erik ^a   Ferrara, Napoleone ^b   Rudolfsson, Stina Häggström ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b GENENTECH INC   (United States)

Author keywords

Androgen receptor; Angiogenesis; Apoptosis; Cell proliferation; Endothelial cell; Stereology; Ventral prostate

Indexed keywords

ANDROGEN RECEPTOR; IMMUNOGLOBULIN G; TESTOSTERONE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ORGAN GROWTH; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE; STEREOLOGY;

ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CASTRATION; CELL DIVISION; ENDOTHELIAL CELLS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SIZE; PROSTATE; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; TESTOSTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0347356345     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10312     Document Type: Article

References (33)

1. Franck Lissbrant I, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001;35:437-552.
2. Lekås E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997;25:309-314.
3. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998;36:201-206.
4. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: Cell death mediated by vascular regression. Curr Opin Urol 2000;10:415-420.
5. Shabisgh A, Tanji N, D'Agati V, Burchardt M, Rubin M, Goluboff ET, Heitjan D, Kiss A, Buttyan R. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999;140:1920-1926.
6. Shabsigh A, Ghafar MA, de la TA, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001;81:437-444.
7. Lekås E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res 1999;27:174-179.
8. Franck-Lissbrant I, Häggström S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998;139:451-456.
9. Lekås E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 2000;85:962-965.
10. Häggström S, Franck-Lissbrant I, Bergh A, Damber JE. Testosterone induces vascular endothelial cell growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999;161:1620-1625.
11. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
12. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-C1366 (Review).
13. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-340.
14. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628.
15. Bergh A, Collin O, Lissbrant E. Effects of acute graded reductions in testicular blood flow on testicular morphology in the adult rat. Biol Reprod 2001;64:13-20.
16. Westin P, Bergh A, Damber JE. Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate but not in the highly differentiated Dunning R-3327PAP prostatic adenocarcinoma. Prostate 1993;22:65-74.
17. Weibel EW. Stereological methods, not a journal-a book published by Academic Press, New York, 1979;1:1-415.
18. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998;139:441-442.
19. Borgström P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10.
20. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999;54:567-572.
21. MacManus JP, Buchan AM, Hill IE, RasQuinda I, Preston E. Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain. Neurosci Lett 1993;164:89-92.
22. Fliss H, Gaittinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996;79:949-956.
23. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
24. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant, and malignant prostate tissues. J Urol 2000;164:506-510.
25. Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001;116:115-121.
26. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432-443.
27. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62:854-859.
28. Isaacs JT, Furya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostate tissue. Semin Cancer Biol 1994;5:391-5400.
29. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998;251:287-290.
30. Isaacs JT, Furya Y, Berges R. Endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
31. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
32. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a preclinical model. J Urol 1999;161:960-963.
33. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;60:970-975.